[Translation] A Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SYN818, a DNA polymerase theta [POLQ] inhibitor, in combination with olaparib in patients with locally advanced or metastatic solid tumors harboring breast cancer susceptibility gene (BRCA) mutations and/or homologous recombination repair (HRR) pathway deficiencies.
评价SYN818与奥拉帕利联合给药在携带BRCA突变和/或HRR通路缺陷的局部晚期或转移性实体瘤受试者中的安全性和耐受性,可能包括确定最大耐受剂量(MTD)和/或II期推荐剂量(RP2D),以及评价SYN818与奥拉帕利联合给药的初步疗效。
[Translation] To evaluate the safety and tolerability of SYN818 in combination with olaparib in subjects with locally advanced or metastatic solid tumors harboring BRCA mutations and/or HRR pathway defects. This may include determining the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), as well as evaluating the preliminary efficacy of the SYN818 in combination with olaparib.